Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $399
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $384 to $399.
August 04, 2023 | 10:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Vertex Pharmaceuticals and raises the price target from $384 to $399.
The news is directly related to Vertex Pharmaceuticals. Barclays' decision to maintain an Overweight rating and raise the price target indicates a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100